

EXHIBIT C1

JUNE FAC								
Drug Name	Date Drug Cosidered by EBD	Use	Current Setup	Recommendation	Rationale	Impacted Members	Cost Per Month	Accept or Reject
TERIPARITIDE INJ	August 2023	osteoporosis	Not Covered	Tier 4, PA	Teriparatide (non-interchangeable generic of Forteo) comes out at a lower WAC compared to Forteo. \$2598 per month compared to \$4164 per month on the Forteo. We will therefore remove Forteo and add teriparatide in its place. Cover with a PA but make sure it is available for people who cannot take zoledronic acid (e.g., have osteonecrosis). If covered, place 24 month lifetime limit on it.	None	\$2,598	
FORTEO INJ	August 2023	osteoporosis	Tier 4	Not Covered	See teriparatide inj.	None	\$4,164	
CORTROPHIN INJ GEL	August 2023	inflammatory immune conditions	N/A	Not Covered	Setting up to match Acthar (NC).	None	\$71,053	
alendronate sodium oral soln	August 2023	osteoporosis	Tier 1	Tier 3	Alendronate solution has had an additional generic manufacturer come to market, which led to the generically named products moving from the previous MONY N to MONY Y. The generics are still priced at just under \$300/month compared to the oral tablets, which cost under \$10/month. As a result, we will be moving these products to the non-preferred brand tier.	None; all currently on tablets	\$300	
sodium sulfacetamide/sulfur wash	August 2023	serborrheic dermatitis (dandruff)	Tier 2	Not Covered	Based on a recent formulary review of sodium sulfacetamide and sodium sulfacetamide/sulfur products, it was determined that certain strengths and dosage forms were substantially more expensive and less utilized than others. Navitus will remove coverage of the more expensive products that cost about \$240 per script.	None	\$240	
OVACE PLUS GEL	August 2023	acne/rosacea	Tier 3	Not Covered	see sodium sulfacetamide/sulfur wash	None	\$240	
sodium sulfacetamide gel	August 2023	acne/rosacea	Tier 3	Not Covered	see sodium sulfacetamide/sulfur wash	None	\$240	
OVACE PLUS SHAMPOO	August 2023	serborrheic dermatitis (dandruff)	Tier 3	Not Covered	see sodium sulfacetamide/sulfur wash	None	\$240	
sodium sulfacetamide shampoo	August 2023	serborrheic dermatitis (dandruff)	Tier 3	Not Covered	see sodium sulfacetamide/sulfur wash	None	\$240	
July FAC								
Drug Name	Date Drug Cosidered by EBD	Use	Current Setup	Recommendation	Rationale	Impacted Members	Cost Per Month	Accept or Reject
glatiramer inj	August 2023	mutiple sclerosis	Tier 4	Tier 4	Keeping at specialty tier due to cost	1	\$2,068	
teriflunamide tab	August 2023	mutiple sclerosis	Tier 4	Tier 4	Keeping at specialty tier due to cost	3	\$1,036	
fingolimod hcl cap 0.5mg	August 2023	mutiple sclerosis	Tier 4	Tier 4	Keeping at specialty tier due to cost	1	\$1,815	
dimethyl fumarate DR starter pack	August 2023	mutiple sclerosis	Tier 4	Tier 1	To enhance the member experience and to allow specialty pharmacies to dispense the lowest cost generic manufacturers, we recommend a new program where specialty generic products will have a member copay that is equivalent to their preferred generic (tier 1) benefit. Additional detailed communication outside of this grid.	None	\$701	
dimethyl fumarate DR cap	August 2023	mutiple sclerosis	Tier 4	Tier 1	To enhance the member experience and to allow specialty pharmacies to dispense the lowest cost generic manufacturers, we recommend a new program where specialty generic products will have a member copay that is equivalent to their preferred generic (tier 1) benefit. Additional detailed communication outside of this grid.	6	\$920	

dalfampridine ER tab	August 2023	mutiple sclerosis	Not Covered	Tier 1	To enhance the member experience and to allow specialty pharmacies to dispense the lowest cost generic manufacturers, we recommend a new program where specialty generic products will have a member copay that is equivalent to their preferred generic (tier 1) benefit. Additional detailed communication outside of this grid.	None; not currently covered	\$104	
sapropterin dihydrochloride soluble tab	August 2023	phenylketonuria	Tier 4, PA	Tier 4, PA	Keeping at specialty tier due to cost	None	\$8,988	
sapropterin dihydrochloride powder packet	August 2023	phenylketonuria	Tier 4, PA	Tier 4, PA	Keeping at specialty tier due to cost	2	\$4,419	
CROTAN LOTION	August 2023	scabies	Tier 3	Not Covered	Cheaper alternatives available. Crotan is over \$2000 per claim, permethrin cream is less than \$300 per claim.	None	\$2,767	
clotrimazole/betamethasone lotion	August 2023	fungal infections of skin	Tier 2	Not Covered	Cheaper alternative available (clotrimazole + betamethasone cream). All utilizing members currently on cream (average \$22.19 per month.	None	\$135	
KALYDECO TAB	August 2023	cystic fibrosis	Tier 4, PA, QL, split fill	Tier 4, PA, QL	Removing split fill program (restricts a medication to a 15-day supply for the first 3 months of treatment). Most SF products are oncology medications, which are very expensive, have frequent intolerance issues, and/or common dose reductions. Looking at utilization for 3 cystic fibrosis drugs in the past year, 3 out of 96 utilizing members stopped therapy with either Kalydeco (ivacaftor), Orkambi (lumacaftor/ivacaftor), or Symdeko (tezacaftor/ivacaftor and ivacaftor) in their first 3 months of therapy. Only 1 of the 3 provided cost savings/waste prevention. No benefit by maintaining SF.	None	\$26,775	
KALYDECO PAK	August 2023	cystic fibrosis	Tier 4, PA, QL, split fill	Tier 4, PA, QL	see KALYDECO TAB	None	\$25,988	
ORKAMBI TAB	August 2023	cystic fibrosis	Tier 4, PA, QL, split fill	Tier 4, PA, QL	see KALYDECO TAB	None	\$22,695	
ORKAMBI GRANULES PACKET	August 2023	cystic fibrosis	Tier 4, PA, QL, split fill	Tier 4, PA, QL	see KALYDECO TAB	None	\$22,670	
SYMDEKO TAB	August 2023	cystic fibrosis	Tier 4, PA, QL, split fill	Tier 4, PA, QL	see KALYDECO TAB	None	\$23,987	
ZEJULA TAB	August 2023	ovarian cancer	Not covered	Not Covered	Recommend continued exclusion of any formulation of Zejula. There is a lack of overall survival and/or quality of life data for its indications (first line maintenance therapy in ovarian cancer and recurrence maintenance therapy in ovarian cancer).  Alternatives recommend: First line maintenance tx: bevacizumab or observation Recurrence maintenance tx: Lynparza (olaparib). Currently Zejula (any form) is excluded from the pharmacy benefit.	None; not currently covered	WAC = \$576.31 per tab	
OMNIPOD GO KIT	August 2023	diabetes	Not covered	Tier 2, QL	New insulin delivery device that recently launched. It has less functionality than the other Omnipod products but is intended for adult patients with type 2 diabetes who use daily injections of long-acting insulin.	None; not currently covered	WAC = \$29.98 per pod	

AUSTEDO XR TAB	August 2023	Huntington's and related diseases	Not covered	Not Covered	An extended release deutetrabenazine product (Austedo XR) recently launched, after establishing efficacy based on a relative bioavailability study comparing once-daily Austedo XR to twice daily Austedo. Requires less frequent daily dosing. Available in 6mg, 123mg, and 24mg strengths. Recommend not covering, as not cost effective based on impact on AIMS scores.	None; single member currently on immediate release	WAC: \$78.68 to \$236.02 per tab	
BCG INJ	August 2023	TB vaccine	Not covered	Standard Vaccine List	Providing additional access to TB vaccination.	None; acute med		
IMOVAX INJ	August 2023	rabies vaccine	Not covered	Standard Vaccine List	Providing additional access to rabies vaccination.	None; acute med	\$457/dose	
RABAVERT INJ	August 2023	rabies vaccine	Not covered	Standard Vaccine List	Providing additional access to rabies vaccination.	None; acute med	\$409-\$429/dose	
Q2 P&T								
Drug Name	Date Drug Cosidered by EBD	Use	Current Setup	Recommendation	Rationale	Impacted Members	Cost per Month	Accept or Reject
Krazati tab (adagrasib)	August 2023	Non-small cell lung cancer, KRAS G12C-mutation	Not covered	Not covered	<p>Recommend continued exclusion of adagrasib and prefer sotorasib. Sotorasib has higher quality data showing it is associated with fewer serious adverse effects compared to standard therapy and possible improvements in quality of life parameters. There is no published clinical trial comparing adagrasib to standard therapy. Its efficacy has been studied in only a single arm trial. From a cost perspective, adding adagrasib to formulary likely would not significantly add additional costs as either sotorasib or adagrasib will be used in this patient population (not both).</p> <p>AWP Sotorasib: \$24,132/30d Adagrasib: \$23,700/30 d</p>	None	\$23,700 if max dose (AWP)	
Lytgobi therapy pack (futibatinib)	August 2023	Intrahepatic bile duct cancer, FGFR2 gene fusion or other rearrangement	Not covered	Tier 4, PA, QL, Split Fill	<p><b>PRO'S:</b> Futibatinib elicited an objective response in 42% of patients that fit the approved indication. Offers another targeted option for a disease with a lack of targeted therapies. Recommended as useful in certain circumstances in NCCN guidelines. <b>CON'S:</b> High incidence of nail toxicity and hyperphosphatemia, and requires regular ophthalmic monitoring for RPED. No active- or placebo-control with which to compare futibatinib. <b>EXPERT OPINION:</b> Futibatinib and pemigatinib are first-choice for patients that meet indication; need more treatments for this rare cancer.</p>	None	\$7002 (AWP)	
Relyvrio Pak (sodium phenylbutyrate/taurursodiol)	August 2023	Amyotrophic Lateral Sclerosis (ALS)	Not covered	Tier 4, PA, QL	Tier 4, PA, QL. The coverage could change to non-covered depending on the results of the PHOENIX trial. To date the CENTAUR-open label extension trial noted a 4.8 month survival benefit over not having the drug. At a minimum, the prescriber should be a board-certified neurologist and the patient must have the diagnosis of ALS. AWP at maintenance dose of 1 packet twice daily is \$195,603 per year per patient.	None	\$15,000 (AWP)	

Mavenclad Therapy Pak (cladribine)	August 2023	Multiple Sclerosis	Not covered	Tier 4, PA, QL	Tier 4, PA, QL. One month includes ~8 or 9 tablets. This, in the past, cost the plan \$73K to 83K per prescription. The dose is weight-based and is given in a 2 year cycle being given for 4-5 consecutive days, then 4-5 consecutive days about 23 days later. During the 2nd year, it is repeated. Then do not administer any more during the following 2 years. All other uses of cladribine require IV or SC dosing. Relapsing remitting MS is the only use for the tablets. One trial showed that patients switching from dimethyl fumarate pre-treatment with cladribine was associated with profound risk of developing severe lymphopenia and subsequent herpes virus infections. IF PA'd, these important clinical findings could be incorporated into the criteria.	None	Range of \$33k to \$88k based on dose. Unique dosing (2 treatment courses per year, 2 courses per cycle)	
Misc								
Drug Name	Date Drug Cosidered by EBD	Use	Current Setup	Recommendation	Rationale	Impacted Members	Cost Per Month	Accept or Reject
MOUNJARO INJ	August 2023	Type 2 Diabetes	Not Covered	Tier 2, RDX	Tirzepatide was studied in five phase III clinical trials lasting 40 to 52 weeks with a variety of background therapies at baseline and continued in the trials. In the trials, tirzepatide was superior to placebo, semaglutide 1 mg, insulin degludec, and insulin glargine for almost all endpoints, including mean A1c change, proportion achieving an A1c under 7.0% (the goal of treatment per ADA guidelines), and body weight reduction. A1c change ranged from -1.87 to -2.58 depending on the strength and trial and weight loss ranged from 7 to 13 kg with more than half of patients achieving at least a 5% weight reduction and 14-47% achieving at least a 15% weight reduction. Awaiting final CV study results. Arkansas currently covers Trulicity. Trulicity rebates will be improved with the addition of Mounjaro.	None; not currently covered	\$1099 (after rebates, net cost is ~\$500)	
PALYNZIQ INJ	August 2023	phenylketonuria	Tier 4, PA, QL	Not Covered	Was included as part of the base formulary as of 7/1. Requesting to remove from formulary. The disease state can be managed through maintaining a PKU-specific diet. Medication is not considered a life-saving or life-prolonging therapy.	None	\$21,000	